Dog Dermatitis Study Gives Struggling KIN Stock a Boost

Despite hitting new lows last week, the brokerage bunch is still incredibly bullish on KIN

Digital Content Manager
Jul 29, 2019 at 9:58 AM
facebook X logo linkedin

Veterinary stock Kindred Biosciences Inc (NASDAQ:KIN) is higher today, after the company announced positive results from a pilot study of KIND-016, used to treat atopic dermatitis in dogs. The equity is eyeing its fourth straight win today, up 8.5% at $7.29, and earnings are just around the corner. 

The stock's surge comes just days after hitting a two-year low of $5.96 on July 23. From a longer-term standpoint, KIN's 80-day moving average has acted as resistance in 2019, ushering the shares to a year-to-date loss of roughly 38%. Now, however, KIN is set to close atop its 10-day moving average for the first time in nearly a month, pacing for its best day since October. 

Despite KIN's struggles in 2019, analysts have been incredibly bullish on KIN, with five calling it a "strong buy," compared to only one analyst saying "hold." What's more, the stock's lofty consensus 12-month target price of $14.81 hasn't been touched since last November, and is more than double the equity's current price. 

Short sellers, on the other hand, have been upping the bearish ante, with short interest up 19.1% in the last two reporting periods. And while the the 1.09 million shares sold short represent only 4% of the stock's available float, it would take more than six days to buy back all these bearish bets, at KIN's average pace of trading.

As alluded to earlier, Kindred Biosciences is slated to report earnings after the close on Thursday, Aug. 1. The stock has averaged a one-day swing of 4.3% after its last eight earnings, regardless of direction, and jumped 3.3% after earnings in May.

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI